Home/Pipeline/RBP-6300 (risperidone)

RBP-6300 (risperidone)

Schizophrenia

Phase 3Active, Not RecruitingNCT06162137

Key Facts

Indication

Schizophrenia

Phase

Phase 3

Status

Active, Not Recruiting

Company

Indivior PLC

About Indivior PLC

Indivior is a mission-driven, publicly traded biopharmaceutical company dedicated to saving lives from the devastating impacts of substance use disorders and mental illness. Its strategic foundation is built upon a 25-year legacy of innovation in buprenorphine-based medication-assisted treatment (MAT), most notably through the commercialization of SUBLOCADE®, a once-monthly injectable that has become the standard of care. Following a strategic redomiciliation to the U.S. and resolution of legacy legal matters, the company is now executing a focused growth strategy to defend its core OUD franchise while advancing a promising pipeline targeting schizophrenia and cocaine use disorder.

View full company profile

Therapeutic Areas

Substance Use Disorders Schizophrenia

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active